Cargando…
Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study
In the Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT‐EXT), extended criteria donor kidney recipients were randomized to receive belatacept‐based (more intense [MI] or less intense [LI]) or cyclosporine‐based immunosuppr...
Autores principales: | Durrbach, A., Pestana, J. M., Florman, S., del Carmen Rial, M., Rostaing, L., Kuypers, D., Matas, A., Wekerle, T., Polinsky, M., Meier‐Kriesche, H. U., Munier, S., Grinyó, J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516151/ https://www.ncbi.nlm.nih.gov/pubmed/27130868 http://dx.doi.org/10.1111/ajt.13830 |
Ejemplares similares
-
Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT
por: Bray, R. A., et al.
Publicado: (2018) -
De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies
por: Bray, R. A., et al.
Publicado: (2018) -
Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017) -
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant
por: Florman, S., et al.
Publicado: (2016) -
Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)